Rossmann Jakob, Antunes Apio C M, Broc Guy G, Chan Danny T M, Chen Se-Yi, Dea Nicolas, Fairhall Jacob, de Andrés Guijarro Pablo, Montano Nicola, Schebesch Karl-Michael, Timothy Jake, Yerramneni Vamsi Krishna
Department of Neurosurgery, Paracelsus Medical University, Nürnberg, Germany.
Neurosurgery Department, Universidade Federal do Rio Grande do Sul and Hospital de Clínicas de Porto Alegre, Porto Alegre, Brazil.
Front Surg. 2025 Aug 20;12:1636372. doi: 10.3389/fsurg.2025.1636372. eCollection 2025.
Postoperative cerebrospinal fluid (CSF) leakage and bleeding are major postoperative complications that increase healthcare system costs. The use of Hemopatch® Sealing Hemostat has been shown to reduce the incidence of such postoperative complications. This technical report aims to provide neurosurgeons with the best recommendations for the effective use of Hemopatch® as a hemostatic and dural sealant in cranial and spinal procedures.
The clinical experiences of 10 neurosurgeons from around the world regarding the use of Hemopatch® were evaluated using an online survey, followed by a hands-on preclinical workshop on adult pigs, which concluded with an in-depth discussion about the use of the patch.
The survey results provide an overview of how and when experts use different types of dural repair materials, including decision-making factors. During the workshop, Hemopatch® presented excellent tissue adherence on all evaluated defects. The new configuration of the patch showed improved tissue adherence, less curling of the patch, and easier removal of the gauze used for compression. Experts recommend using patches that overlap the defect for ≥1 cm. When closing defects that do not allow for a dried application site, Hemopatch® can be put on a dry gauze, which can be bent into a U-shape. This allows better targeting of the application site and enables immediate compression upon placement.
The results provide information to improve the hands-on use of Hemopatch® as a dural sealant, therefore reducing the risk of postoperative complications such as CSF leaks, eventually reducing healthcare system costs.
术后脑脊液漏和出血是增加医疗系统成本的主要术后并发症。已证明使用Hemopatch®密封止血剂可降低此类术后并发症的发生率。本技术报告旨在为神经外科医生提供关于在颅脑和脊柱手术中有效使用Hemopatch®作为止血剂和硬脑膜密封剂的最佳建议。
通过在线调查评估了来自世界各地的10位神经外科医生使用Hemopatch®的临床经验，随后在成年猪身上进行了实践前临床研讨会，最后对该贴片的使用进行了深入讨论。
调查结果概述了专家如何以及何时使用不同类型的硬脑膜修复材料，包括决策因素。在研讨会上，Hemopatch®在所有评估的缺损处均表现出出色的组织粘附性。贴片的新构型显示出改善的组织粘附性、更少的贴片卷曲以及更容易去除用于压迫的纱布。专家建议使用与缺损重叠≥1厘米的贴片。当封闭不允许应用部位干燥的缺损时，Hemopatch®可放置在干燥的纱布上，纱布可弯曲成U形。这使得应用部位的靶向性更好，并在放置时能够立即进行压迫。
这些结果提供了信息，以改善Hemopatch®作为硬脑膜密封剂的实际使用，从而降低脑脊液漏等术后并发症的风险，最终降低医疗系统成本。
